Witzig TE - Search Results

1

Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

Wiseman GA, Conti PS, Vo K, Schilder RJ, Gordon LI, Emmanouilides C, Silverman DH, Witzig TE, Darif M, Molina A. Wiseman GA, et al. Among authors: witzig te. Clin Lymphoma Myeloma. 2007 Sep;7(8):514-7. doi: 10.3816/clm.2007.n.035. Clin Lymphoma Myeloma. 2007. PMID: 18021468 Clinical Trial.

2

Primary renal non-Hodgkin's lymphoma. An unusual extranodal site.

Okuno SH, Hoyer JD, Ristow K, Witzig TE. Okuno SH, et al. Among authors: witzig te. Cancer. 1995 May 1;75(9):2258-61. doi: 10.1002/1097-0142(19950501)75:9<2258::aid-cncr2820750911>3.0.co;2-s. Cancer. 1995. PMID: 7712433 Review.

3

Refractory and relapsing multiple myeloma treated by blood stem cell transplantation.

Gertz MA, Pineda AA, Chen MG, Letendre L, Greipp PR, Solberg LA Jr, Witzig TE, Garton JP, Inwards DJ, Litzow MR, et al. Gertz MA, et al. Among authors: witzig te. Am J Med Sci. 1995 Mar;309(3):152-61. doi: 10.1097/00000441-199503000-00006. Am J Med Sci. 1995. PMID: 7879820

4

Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues.

Witzig TE, Weitz JJ, Lundberg JH, Tefferi A. Witzig TE, et al. Leuk Lymphoma. 1994 Jun;14(1-2):137-9. doi: 10.3109/10428199409049659. Leuk Lymphoma. 1994. PMID: 7920220

5

Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma.

Tefferi A, Witzig TE, Reid JM, Li CY, Ames MM. Tefferi A, et al. Among authors: witzig te. J Clin Oncol. 1994 Mar;12(3):569-74. doi: 10.1200/JCO.1994.12.3.569. J Clin Oncol. 1994. PMID: 8120555 Clinical Trial.

6

A phase I trial of high dose ProMACE-CytaBOM with granulocyte colony stimulating factor for patients with non-Hodgkin's lymphoma.

Witzig TE, Camoriano JK, Schroeder G, Kurtin PJ, Habermann TM. Witzig TE, et al. Leuk Lymphoma. 1998 Jan;28(3-4):307-14. doi: 10.3109/10428199809092686. Leuk Lymphoma. 1998. PMID: 9517502 Clinical Trial.

7

Evaluation of the proliferative index as a prognostic factor in diffuse large cell lymphoma: correlation with the International Index.

Ansell SM, Kurtin PJ, Stenson M, Habermann TM, Greipp PR, Therneau TM, Witzig TE. Ansell SM, et al. Among authors: witzig te. Leuk Lymphoma. 1999 Aug;34(5-6):529-37. doi: 10.3109/10428199909058480. Leuk Lymphoma. 1999. PMID: 10492076

8

Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody.

Wiseman GA, White CA, Witzig TE, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Grillo-López AJ. Wiseman GA, et al. Among authors: witzig te. Clin Cancer Res. 1999 Oct;5(10 Suppl):3281s-3286s. Clin Cancer Res. 1999. PMID: 10541376 Review.

9

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.

Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DH, Parker E, Grillo-López AJ. Witzig TE, et al. J Clin Oncol. 1999 Dec;17(12):3793-803. doi: 10.1200/JCO.1999.17.12.3793. J Clin Oncol. 1999. PMID: 10577851 Clinical Trial.

10

Delayed stem cell transplantation for the management of relapsed or refractory multiple myeloma.

Gertz MA, Lacy MQ, Inwards DJ, Gastineau DA, Tefferi A, Chen MG, Witzig TE, Greipp PR, Litzow MR. Gertz MA, et al. Among authors: witzig te. Bone Marrow Transplant. 2000 Jul;26(1):45-50. doi: 10.1038/sj.bmt.1702445. Bone Marrow Transplant. 2000. PMID: 10918404

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

640 results

Search Page

Filters